- Report
- July 2022
- 161 Pages
Global
From €1832EUR$2,000USD£1,559GBP
- Report
- January 2023
- 204 Pages
Global
From €3297EUR$3,600USD£2,807GBP
- Report
- January 2023
- 88 Pages
Europe
From €1374EUR$1,500USD£1,170GBP
- Drug Pipelines
- December 2022
- 127 Pages
Global
From €13733EUR$14,995USD£11,692GBP
- Report
- December 2021
- 124 Pages
Global
From €10069EUR$10,995USD£8,573GBP
- Report
- August 2022
United States
From €1777EUR$1,940USD£1,513GBP
- Report
- August 2022
Global
From €907EUR$990USD£772GBP
- Report
- August 2021
Global
From €3654EUR$3,990USD£3,111GBP
- Report
- August 2024
- 99 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- December 2022
- 220 Pages
Global
From €2289EUR$2,499USD£1,949GBP
€3269EUR$3,570USD£2,784GBP
The Endometriosis Drug market is a subset of the Immune Disorders Drugs market. Endometriosis is a condition in which the tissue that normally lines the uterus grows outside of the uterus, causing pain and other symptoms. Endometriosis drugs are used to treat the symptoms of endometriosis, such as pain, heavy menstrual bleeding, and infertility. These drugs can be divided into two categories: hormonal therapies and non-hormonal therapies. Hormonal therapies include oral contraceptives, progestins, and gonadotropin-releasing hormone agonists. Non-hormonal therapies include non-steroidal anti-inflammatory drugs, danazol, and GnRH antagonists.
Some companies in the Endometriosis Drug market include AbbVie, Allergan, Bayer, Merck, and Pfizer. Show Less Read more
